Business
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program
CHICAGO, March 25, 2026--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568) aimed at accelerating the clinical development and differentiation of an antibody drug conjugate (ADC) program in oncology.
About this update from Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f925e240cc1193b45fd29560053defbd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Wpfr44Azy9tn3RmxeR7Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/f925e240cc1193b45fd29560053defbd","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Qfc73lAOl49FUzOApP5bYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/f925e240cc1193b45fd29560053defbd","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, March 25, 2026--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568) aimed at accelerating the clinical development and differentiation of an antibody drug conjugate (ADC) program in oncology.","length":316,"tagName":"p"},{"type":"text","content":"Through this collaboration, Daiichi Sankyo will leverage Tempus’ proprietary foundation models and AI expertise, including PRISM2, a state-of-the-art, multimodal foundation model that combines pathology images and clinical data to generate rich diagnostic and predictive insights. By combining clinical trial and preclinical research data from Daiichi Sankyo with Tempus’ comprehensive real-world data, the collaboration aims to unlock new opportunities for biomarker discovery and patient stratification.","length":505,"tagName":"p"},{"type":"text","content":"Tempus and Daiichi Sankyo will develop proof-of-concept AI models to optimize patient selection and increase probability of success for a novel ADC. By deploying these models across Tempus’ expansive oncology database, the collaboration will generate detailed response maps, enabling precise patient stratification and supporting rigorous benchmarking of potential control arms for future clinical trials.","length":405,"tagName":"p"},{"type":"text","content":""Our collaboration with Daiichi Sankyo signals a new chapter in how multimodal AI and real-world data can be applied to advance the development of ADCs," said Ryan Fukushima, CEO of Data and Apps at Tempus. "Our multimodal foundation mod...